SCHEMBL8924537

SCHEMBL8924537

Cc1nc(/N=N/C(=N/Nc2ccccc2)c2ccccc2)sc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.50
TDP1 Q9NUW8 6/20 0.50
MAPT P10636 6/20 0.50
HTT P42858 5/20 0.50
GAA P10253 5/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
KDM4E B2RXH2 3/20 0.50
MAPK1 P28482 3/20 0.50
HSP90AA1 P07900 1/20 0.50
NPC1 O15118 6/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 3/20 0.46
HPGD P15428 1/20 0.46
ALOX12 P18054 1/20 0.46
LMNA P02545 1/20 0.43
PKM P14618 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
PTBP1 P26599 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2619262 1.00 RAB9A (0.50) RAB9ATDP1MAPTHTTGAA
SCHEMBL745118 1.00 RAB9A (0.50) RAB9ATDP1MAPTHTTGAA
SCHEMBL11332706 0.83 MAPT (0.52) RAB9ATDP1MAPTHTTGAA
SCHEMBL11327606 0.83 MAPT (0.52) RAB9ATDP1MAPTHTTGAA
SCHEMBL745116 0.77 RAB9A (0.49) RAB9ATDP1MAPTHTTGAA
SCHEMBL745117 0.77 RAB9A (0.49) RAB9ATDP1MAPTHTTGAA
SCHEMBL21838458 0.77 RAB9A (0.49) RAB9ATDP1MAPTHTTGAA
SCHEMBL21838460 0.77 RAB9A (0.49) RAB9ATDP1MAPTHTTGAA
SCHEMBL30220799 0.77 RAB9A (0.49) RAB9ATDP1MAPTHTTGAA
SCHEMBL15992321 0.74 KMT2A (0.37) RAB9ATDP1MAPTHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11650203-B2 One-pot biosensor and immunoassay method using the same GIST (Gwangju Institute of Science and Technology) (KR) 2023-05-16 US claimed
US-12636325-B2 Probiotic compositions for treating and preventing colorectal cancer THE CHINESE UNIVERSITY OF HONG KONG (CN) 2026-05-26 US disclosed
CN-116768801-B Condensed quinone oxime imidazoles and their onium derivatives, their preparation and use 上海交通大学 2026-05-19 CN disclosed
US-12630589-B2 Compounds for use in viral infections PHARMA MAR, S.A. (ES) 2026-05-19 US disclosed
CN-122038528-A LDHA enzyme activity detection method based on MTS color development system 深圳大学 2026-05-15 CN disclosed
CN-119954744-B Aspirin-sulfonamide hybrid, and preparation method and application thereof 宁夏大学 2026-05-15 CN disclosed
WO-2026100855-A1 METHOD FOR PREPARING EXOSOMES ISOLATED FROM WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELLS, AND COSMETIC MATERIAL COMPOSITION COMPRISING EXOSOMES PREPARED USING SAME 주식회사 파나셀바이오텍 2026-05-15 WO disclosed
US-12616681-B2 Compositions and methods for treating renal injury CASE WESTERN RESERVE UNIVERSITY (US) 2026-05-05 US disclosed
US-12605485-B2 Nanoparticles to promote wound healing and antimicrobial infection control KISMET TECHNOLOGIES INC. (US) 2026-04-21 US disclosed
US-12599698-B2 Therapeutic article of manufacture with nanoparticles to promote wound healing and/or antimicrobial infection control KISMET TECHNOLOGIES INC. (US) 2026-04-14 US disclosed
US-10544140-B2 Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof LG CHEM, LTD. (KR) 2020-01-28 US disclosed
US-20180370964-A1 PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, 7-AZAINDOLIN-2-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF LG CHEM, LTD. (KR) 2018-12-27 US disclosed
EP-3363799-A1 PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, 7-AZAINDOLIN-2-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF LG Chem, Ltd. (KR) 2018-08-22 EP disclosed
US-8188144-B2 In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells ANTOXIS LIMITED (GB) 2012-05-29 US disclosed
US-8188144-B2 In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells ANTOXIS LIMITED (GB) 2012-05-29 US disclosed
US-20100267132-A1 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS ANTOXIS LIMITED (GB) 2010-10-21 US disclosed
US-20100267132-A1 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS ANTOXIS LIMITED (GB) 2010-10-21 US disclosed
WO-2009047568-A2 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS ANTOXIS LIMITED (GB) 2009-04-16 WO disclosed
US-4292399-A Cobalt (III) complex imaging compositions having improved photographic properties EASTMAN KODAK COMPANY (US) 1981-09-29 US disclosed
US-4171221-A NONSILVER PHOTOGTAPHY EASTMAN KODAK COMPANY (US) 1979-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180370964-A1 PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, 7-AZAINDOLIN-2-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF HDAC6, AZI2, HDAC7 RAB9A 456/4885TDP1 4034/4885MAPT 2452/4885
US-10544140-B2 Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof AZI2, HDAC7, CYP3A7 RAB9A 779/4885TDP1 1403/4885MAPT 3389/4885
US-12616681-B2 Compositions and methods for treating renal injury PTGIS, PTGS1, PTGS2 RAB9A 3504/4885TDP1 4727/4885MAPT 4830/4885
US-20100267132-A1 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS PIGS, AQP1, F12 RAB9A 3789/4885TDP1 1755/4885MAPT 3710/4885
US-12599698-B2 Therapeutic article of manufacture with nanoparticles to promote wound healing and/or antimicrobial infection control ARG1, CD68, MIF RAB9A 3160/4885TDP1 3313/4885MAPT 1219/4885
US-12630589-B2 Compounds for use in viral infections MIF, MAVS, NISCH RAB9A 3267/4885TDP1 2448/4885MAPT 1389/4885
US-12605485-B2 Nanoparticles to promote wound healing and antimicrobial infection control CUTA, ITGB3, ITGA2 RAB9A 2680/4885TDP1 3557/4885MAPT 2972/4885
US-12636325-B2 Probiotic compositions for treating and preventing colorectal cancer LCT, SI, LDHA RAB9A 2453/4885TDP1 4305/4885MAPT 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.